



Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has four novel and differentiated drug development programs. OLINVYK® is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at [OLINVYK.com](https://www.olinvyk.com). The company has three investigational drug candidates, including TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. The company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating diabetic neuropathic pain, epilepsy, and other CNS disorders.

Trevena Reports Third Quarter 2024 Results and Provides Business Update

Nov 7 2024, 7:01 AM EST

Trevena Announces Receipt of Nasdaq Delisting Notification

Oct 4 2024, 4:05 PM EDT

Trevena Announces Reverse Stock Split

Aug 8 2024, 4:05 PM EDT

Stock Overview

Symbol	TRVN
Exchange	OTCID
Market Cap	237.54k
Last Price	\$0.27
52-Week Range	\$0.25 - \$7.85

08/18/2025 02:49 PM EDT

Trevena, Inc.

2870 Peachtree Road
Suite 502
Atlanta, GA 30305

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.